ASD Aggression Treatment via Tri-Drug Composition
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current antipsychotic medications used to treat Autism Spectrum Disorder (ASD) aggression and paranoia/social isolation often lead to irreversible tardive dyskinesia, dystonias, and tachyphylaxis, posing significant side effects and loss of effectiveness over long-term use.
Innovation Solution
A novel combination of fluoxetine or sertraline with guanfacine and oxcarbazepine, administered in pharmacologically effective doses twice daily, replaces traditional antipsychotics to manage ASD aggression and paranoia without the risk of dystonias and tachyphylaxis, leveraging the serotonin reuptake inhibition and anti-epileptic properties of these drugs.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If traditional antipsychotic medications (haloperidol, risperidone, aripiprazole) are used to treat ASD aggression and paranoia, then symptom control is achieved, but irreversible tardive dyskinesia and dystonias develop
Solution Approach 1:
The patent segments the treatment approach by dividing the single-drug antipsychotic regimen into a multi-component composition: an atypical antipsychotic (risperidone or aripiprazole) combined with a serotonin reuptake inhibitor (fluoxetine or sertraline) and memantine. This segmentation allows reduction of the antipsychotic dosage while maintaining symptom control and reducing dystonia risk through the additive effects of the other components.
Solution Approach 2:
The patent creates a composite treatment regimen combining three different pharmacological agents with distinct mechanisms of action: dopamine antagonism (antipsychotic), serotonin reuptake inhibition (SSRI), and NMDA receptor modulation (memantine). This composite approach addresses multiple pathophysiological pathways involved in ASD aggression and paranoia, enabling effective symptom management with lower doses of each individual agent, thereby reducing the risk of tardive dyskinesia and dystonias.
2Reliability
If long-term use of antipsychotic medications is continued to maintain symptom control, then aggression and paranoia are managed, but tachyphylaxis (loss of effectiveness) occurs
Solution Approach 1:
The patent ensures continuous and complementary pharmacological action by combining three medications that work through different mechanisms. The antipsychotic provides dopamine antagonism, the SSRI provides serotonin reuptake inhibition, and memantine provides NMDA receptor modulation. This continuous multi-mechanism action prevents tachyphylaxis by engaging multiple neural pathways simultaneously, maintaining therapeutic effectiveness over the long term without the diminishing returns seen with single-agent therapy.
Solution Approach 2:
The patent changes the pharmacological parameters of the treatment regimen by introducing agents that target different neurotransmitter systems (serotonin via SSRIs, glutamate via memantine) in addition to the dopamine system targeted by antipsychotics. This parameter diversification creates a more robust and sustained therapeutic effect that resists tachyphylaxis, as the multiple mechanisms compensate for any single pathway adaptation or tolerance development over time.
3Reliability
If newer generation antipsychotics (risperidone, aripiprazole) are used to treat ASD, then aggression and paranoia are treated, but significant weight gain occurs
Solution Approach 1:
The patent segments the therapeutic burden by distributing the treatment function across three medications, allowing the antipsychotic to be used at lower doses. The SSRI component (fluoxetine or sertraline) addresses serotonin-related behaviors, and memantine addresses glutamate-related symptoms. This segmentation reduces the total dose of the weight-gaining antipsychotic while maintaining overall treatment effectiveness, thereby mitigating weight gain as a side effect.
Solution Approach 2:
The composite regimen combines three agents with different side effect profiles. By incorporating SSRIs and memantine into the treatment, the patent creates a balanced composition where the weight-gaining potential of the antipsychotic is offset by the weight-neutral or weight-managing properties of the other components, particularly memantine which has a favorable metabolic profile and SSRIs that can actually promote weight loss in some patients.
Data Source
AI summary
Autism (ASD) symptoms of aggression-toward others or self, and paranoia with social isolation, are presently treated with antipsychotic medications such as haloperidol, Thorazine, and newer generation antipsychotics risperidone and aripiprazole (latter two are the only FDA approved drugs for treating autism irritability/aggression). But these antipsychotics including the newer generation, after a two or more years of use, often lead to irreversible tardive dyskinesia, other dystonias, loss of effectiveness, and brain volume loss. The present invention overcomes the irreversible tardive dyskinesia and dystonias and loss of effectiveness with long term-use of antipsychotics, by replacing the antipsychotic completely with a three (3) drug novel composition consisting of fluoxetine or sertraline with guanfacine and oxcarbazepine. This novel composition markedly reduces aggression and paranoia/social isolation in ASD adults and adolescents without concomitant antipsychotic use that often causes irreversible tardive dyskinesia, eventual tachyphylaxis, or brain volume loss from antipsychotic long-term use.